"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED ACCELERATED APPROVAL TO BRIGATINIB (ALUNBRIG) FOR THE TREATMENT OF PATIENTS WITH ALK- POSITIVE NSCLC

FDA GRANTED ACCELERATED APPROVAL TO BRIGATINIB (ALUNBRIG) FOR THE TREATMENT OF PATIENTS WITH ALK- POSITIVE NSCLC

01 May 2017 9:01 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to brigatinib (Alunbrig) for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Read the full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software